Clinical Trial: Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07214779) titled 'Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression' on Oct. 06.

Brief Summary: The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

Study Start Date: Dec. 01

Study Type: INTERVENTIONAL

Condition: Ovarian Cancer

Intervention: DRUG: INCB123667

Oral; tablet

DRUG: Investigator's choice of chemotherapy

The investigator will select the chemotherapy in accordance with the protocol-defined requirem...